摘要
目的 :探讨来氟米特治疗复发性肾病综合征(nephrotic syndrome,NS)的疗效及对血清炎症因子水平的影响。方法 :选取2014年6月—2016年1月我院收治的110例复发性NS患者作为研究对象,按随机数字表法分成两组,各55例。对照组采用常规治疗,干预组在对照组基础上加用来氟米特(30 mg,qd,po,连续服用3d,后改为20 mg,qd,连续服用4个月,最后改为10 mg,qd,维持治疗至1年)治疗,观察并比较两组疗效、血液指标、肝功能指标、肾功能指标、炎症因子水平及不良反应指标变化情况。结果:干预组治疗总有效率为93.64%,显著高于对照组的67.27%(P <0.05);两组治疗前、治疗末红细胞、白细胞、血红蛋白、血小板、丙氨酸氨基转移酶、天冬氨酸氨基转移酶含量比较,差异无统计学意义(P> 0.05);两组治疗末24 h尿蛋白、尿素氮、肌酐水平较治疗前均显著降低,白蛋白水平显著升高,且干预组以上指标变化显著优于对照组(P <0.05);两组治疗4个月后、治疗末白细胞介素(IL)-1、IL-6、IL-10、肿瘤坏死因子(TNF)-α较治疗前均显著下降,且干预组低于同期对照组(P <0.05)。结论 :来氟米特治疗复发性NS的疗效确切,可降低炎症因子水平,保护肾功能。
Objective: To investigate the efficacy of leflunomide in the treatment of recurrent nephrotic syndrome (NS) and its effect on serum inflammatory factor levels. Methods: 110 patients with recurrent NS admitted to our hospital from June 2014 to January 2016 were selected as subjects investigated and randomly divided into two groups, 55 patients in each group. The patients in the control group were given conventional therapy. The patients in the intervention group were further given leflunomide (30 mg, qd, po for 3 days, then changed to 20 mg, qd for 4 months, and finally changed to 10 mg, qd, maintenance treatment to 1 year) treatment. The efficacy and changes in blood indexes, liver function indexes, renal function indexes, inflammatory factors and adverse reaction indexes in the two groups were observed and compared. Results: The total effective rate in the intervention group was 93.64%, which was significantly higher than that in the control group (P<0.05). There were no significant differences in erythrocyte, leukocyte, hemoglobin, platelet, alanine aminotransferase and aspartate aminotransferase before treatment and at the end of treatment between the two groups (P>0.05). The levels of 24 h urinary protein, urea nitrogen and creatinine in the two groups at the end of treatment were significantly lower than those before treatment, while the level of albumin was significantly increased, and the changes in the above indexes in the intervention group were significantly better than those in the control group (P<0.05). The levels of interleukin (IL)-1, IL-6. IL-10 and tumor necrosis factor (TNF)-α in the two groups after 4 months of treatment and at the end of treatment were significantly lower than those before treatment, and the levels in the intervention group were lower than those in the control group (P<0.05). Conclusion: Leflunomide has definite efficacy in the treatment of recurrent NS, and can reduce inflammatory factor levels and protect kidney function.
作者
李海燕
王学珍
严鸣光
Li Hai-yan;Wang Xue-zhen;Yan Ming-guang(Department of Nephrology and Rheumatology,the First People’s Hospital of Shangqiu City,Henan Shangqiu 476100,China)
出处
《中国执业药师》
CAS
2018年第11期6-10,共5页
China Licensed Pharmacist
关键词
来氟米特
复发性肾病综合征
临床效果
炎症因子
Leflunomide
Recurrent Nephrotic Syndrome
Clinical Effect
Inflammatory Factor
